DeepLife and 3Billion partner for genetic drug discovery
Parisian artificial intelligence company DeepLife and South Korean genomics firm 3Billion have announced a partnership to develop small-molecule treatments against new drug targets with a focus on genetic modifiers. The agreement integrates the TwinCell virtual cell platform with genomic data from more than 110,000 individuals.